Evidence map›Paper›PMID 18431743›Full record

ArticleInternational journal of cancer2008

Consortium analysis of 7 candidate SNPs for ovarian cancer.

Susan J Ramus, Robert A Vierkant, Sharon E Johnatty, Malcolm C Pike, David J Van Den Berg, Anna H Wu, Celeste Leigh Pearce, Usha Menon, Aleksandra Gentry-Maharaj, Simon A Gayther and 37 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 7 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 7 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors at 20 institutions in 6 countries.

Susan J RamusTranslational Research Laboratory, University College London EGA Institute for Women's Health, London, United Kingdom.
Robert A VierkantCollege of Medicine, Mayo Clinic, Rochester, MN.
Sharon E JohnattyThe Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia.
Malcolm C PikeUniversity of Southern California, Keck School of Medicine, Los Angeles, CA.
David J Van Den BergUniversity of Southern California, Keck School of Medicine, Los Angeles, CA.
Anna H WuUniversity of Southern California, Keck School of Medicine, Los Angeles, CA.
Celeste Leigh PearceUniversity of Southern California, Keck School of Medicine, Los Angeles, CA.
Usha MenonGynaecological Cancer Research Centre, University College London, EGA Institute for Women's Health, London, United Kingdom.
Aleksandra Gentry-MaharajGynaecological Cancer Research Centre, University College London, EGA Institute for Women's Health, London, United Kingdom.
Simon A GaytherTranslational Research Laboratory, University College London EGA Institute for Women's Health, London, United Kingdom.
Richard A DiCioccioRoswell Park Cancer Institute, Buffalo, NY.
Valerie McGuireStanford University School of Medicine, Stanford, CA.
Alice S WhittemoreStanford University School of Medicine, Stanford, CA.
Honglin SongCancer Research United Kingdom Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Douglas F EastonCancer Research United Kingdom Genetic Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Paul D P PharoahCancer Research United Kingdom Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.
Stephen ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, Cancer Center and M. Sklodowska-Curie Institute of Oncology, Warsaw, Poland.
Louise BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA.
Shelley S TworogerChanning Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Susan E HankinsonChanning Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC.
Patricia G MoormanDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC.
Joellen M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC.
Julie M CunninghamCollege of Medicine, Mayo Clinic, Rochester, MN.
Mark LiebowCollege of Medicine, Mayo Clinic, Rochester, MN.
Susanne Krüger KjaerDanish Cancer Society, Copenhagen, Denmark.
Estrid HogdallDanish Cancer Society, Copenhagen, Denmark.
Claus HogdallRigshospitalet, The Juliane Marie Centre, University of Copenhagen, Copenhagen, Denmark.
Jan BlaakaerAarhus University Hospital, Skejby, Denmark.
Roberta B NessGraduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Kirsten B MoysichRoswell Park Cancer Institute, Buffalo, NY.
Robert P EdwardsMagee-Womens Hospital, Pittsburgh, PA.
Michael E CarneyCancer Research Center, University of Hawaii, Honolulu, Hawaii.
Galina LurieCancer Research Center, University of Hawaii, Honolulu, Hawaii.
Marc T GoodmanCancer Research Center, University of Hawaii, Honolulu, Hawaii.
Shan Wang-GohrkeUniversity of Ulm, Ulm, Germany.
Silke KroppDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Penelope M WebbThe Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia.
Xiaoqing ChenThe Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia.
Jonathan BeesleyThe Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia.
Georgia Chenevix-TrenchThe Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia.
Ellen L GoodeCollege of Medicine, Mayo Clinic, Rochester, MN.
QIMR Berghofer Medical Research Institute · AUBrigham and Women's Hospital · USMayo Clinic · USUniversity of Southern California · USDivision of Cancer Epidemiology and GeneticsCancer Research UK · GBDanish Cancer Society · DKDuke Medical Center · USNational Institute for Health Research · GBRoswell Park Comprehensive Cancer Center · USStanford University · USUniversity College London · GBAarhus University Hospital · DKCancer Center of Hawaii · USCancer Research Center · USDuke University Hospital · USGerman Cancer Research Center · DEHeidelberg University · DEMagee-Womens Hospital · USThe Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 1985 to 2009
$18.2M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Inflammation and Ovarian CancerR01CA095023 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUNKER, CLAREANN H. · 2003 to 2008
$2.7M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSU01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1996 to 2000
$943k
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSK07CA080668 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MODUGNO, FRANCESMARY · 2000 to 2005
$661k
Cancer Research UK 10118NCI NIH HHS 1-R01-CA76016NCI NIH HHS CA015083NCI NIH HHS CA122443NCI NIH HHS CA14089NCI NIH HHS CA16056NCI NIH HHS CA17054NCI NIH HHS CA58598NCI NIH HHS CA61132NCI NIH HHS CA63464NCI NIH HHS CA71766NCI NIH HHS K07 CA080668NCI NIH HHS K07-CA80668NCI NIH HHS N01 CA015083NCI NIH HHS N01-CN-67001NCI NIH HHS N01 PC035137NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA095023NCI NIH HHS R01CA095023NCI NIH HHS R01 CA122443NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS U01 CA063464
6 · The paper itself

Abstract

The Ovarian Cancer Association Consortium selected 7 candidate single nucleotide polymorphisms (SNPs), for which there is evidence from previous studies of an association with variation in ovarian cancer or breast cancer risks. The SNPs selected for analysis were F31I (rs2273535) in AURKA, N372H (rs144848) in BRCA2, rs2854344 in intron 17 of RB1, rs2811712 5' flanking CDKN2A, rs523349 in the 3' UTR of SRD5A2, D302H (rs1045485) in CASP8 and L10P (rs1982073) in TGFB1. Fourteen studies genotyped 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non-Hispanic origin. A marginally significant association was found for RB1 when all studies were included [ordinal odds ratio (OR) 0.88 (95% confidence interval (CI) 0.79-1.00) p = 0.041 and dominant OR 0.87 (95% CI 0.76-0.98) p = 0.025]; when the studies that originally suggested an association were excluded, the result was suggestive although no longer statistically significant (ordinal OR 0.92, 95% CI 0.79-1.06). This SNP has also been shown to have an association with decreased risk in breast cancer. There was a suggestion of an association for AURKA, when one study that caused significant study heterogeneity was excluded [ordinal OR 1.10 (95% CI 1.01-1.20) p = 0.027; dominant OR 1.12 (95% CI 1.01-1.24) p = 0.03]. The other 5 SNPs in BRCA2, CDKN2A, SRD5A2, CASP8 and TGFB1 showed no association with ovarian cancer risk; given the large sample size, these results can also be considered to be informative. These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach.

Indexed as

MutationPolymorphism, Single Nucleotide3-Oxo-5-alpha-Steroid 4-DehydrogenaseApoptosis Regulatory ProteinsAurora Kinase AAurora KinasesBRCA2 ProteinBreast NeoplasmsCarcinomaCase-Control StudiesCaspase 8Cyclin-Dependent Kinase Inhibitor p16FemaleGenotypeHumansNeoplasm Proteins3-Oxo-5-alpha-Steroid 4-DehydrogenaseApoptosis Regulatory ProteinsAURKA protein, humanAurora Kinase AAurora KinasesBLID protein, humanBRCA2 ProteinBRCA2 protein, humanCASP8 protein, humanCaspase 8Cyclin-Dependent Kinase Inhibitor p16Neoplasm ProteinsProtein Serine-Threonine KinasesRetinoblastoma ProteinTransforming Growth Factor beta1

Identifiers

PMID18431743
PMCPMC2667795
OpenAlexW2053323942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.